Full Text Journal Articles in
Journal Blood Adv

Advertisement

Find full text journal articles






Safety of a strategy combining D-dimer testing and whole-leg ultrasonography to rule out deep vein thrombosis.

Synne G Fronas, Camilla T Jørgensen, Anders E A Dahm, Hilde S Wik, Jostein Gleditsch, Nezar Raouf, René Holst, F A Klok, Waleed Ghanima,

Guidelines for the diagnostic workup of deep vein thrombosis (DVT) recommend assessing the clinical pretest probability before proceeding to D-dimer testing and/or compression ultrasonography (CUS) if the patient has high pretest probability or positive D-dimer. Referring only patients with positive D-dimer for whole-leg CUS irrespective of pretest probability may simplify ... Read more >>

Blood Adv (Blood advances)
[2020, 4(20):5002-5010]

Cited: 0 times

View full text PDF listing >>



Naive T-cell depletion in stem cell transplantation.

Marie Bleakley,

Allogeneic hematopoietic stem cell transplantation (HCT) is curative in many patients with advanced hematopoietic malignancies. Donor T cells not only facilitate engraftment and protect against opportunistic pathogens and residual disease, but can also cause graft-versus-host disease (GVHD), with significant morbidity and mortality. Complete T-cell depletion can not only substantially reduce ... Read more >>

Blood Adv (Blood advances)
[2020, 4(19):4980]

Cited: 0 times

View full text PDF listing >>



Advertisement

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma.

Frederick L Locke, John M Rossi, Sattva S Neelapu, Caron A Jacobson, David B Miklos, Armin Ghobadi, Olalekan O Oluwole, Patrick M Reagan, Lazaros J Lekakis, Yi Lin, Marika Sherman, Marc Better, William Y Go, Jeffrey S Wiezorek, Allen Xue, Adrian Bot,

ZUMA-1 demonstrated a high rate of durable response and a manageable safety profile with axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients with refractory large B-cell lymphoma. As previously reported, prespecified clinical covariates for secondary end point analysis were not clearly predictive of efficacy; these ... Read more >>

Blood Adv (Blood advances)
[2020, 4(19):4898-4911]

Cited: 0 times

View full text PDF listing >>



Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM.

Neeraj Saini, Qaiser Bashir, Denái R Milton, Guilin Tang, Ruby Delgado, Gabriela Rondon, Uday R Popat, Chitra M Hosing, Yago Nieto, Partow Kebriaei, Amin M Alousi, Rohtesh Mehta, Samer Srour, Issa F Khouri, Donna M Weber, Sheeba K Thomas, Hans C Lee, Krina K Patel, Robert Z Orlowski, Richard E Champlin, Muzaffar H Qazilbash,

Blood Adv (Blood advances)
[2020, 4(19):4834-4837]

Cited: 0 times

View full text PDF listing >>



Hodges JR, Phillips SM, Norell S, et al. Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study. Blood Adv. 2020;4(18):4463-4473.

Blood Adv (Blood advances)
[2020, 4(19):4822]

Cited: 0 times

View full text PDF listing >>



BCL-XL inhibition by BH3-mimetic drugs induces apoptosis in models of Epstein-Barr virus-associated T/NK-cell lymphoma.

Nenad Sejic, Lindsay C George, Rosemary J Tierney, Catherine Chang, Olga Kondrashova, Ruth N MacKinnon, Ping Lan, Andrew I Bell, Guillaume Lessene, Heather M Long, Andreas Strasser, Claire Shannon-Lowe, Gemma L Kelly,

Epstein-Barr virus (EBV)-associated T- and natural killer (NK)-cell malignancies, such as extranodal NK-/T-cell lymphoma (ENKTL), exhibit high chemoresistance and, accordingly, such patients have a poor prognosis. The rare nature of such cancers and nonmalignant T/NK lymphoproliferative disorders, such as chronic active EBV (CAEBV), has limited our understanding of the pathogenesis ... Read more >>

Blood Adv (Blood advances)
[2020, 4(19):4775-4787]

Cited: 0 times

View full text PDF listing >>



Human ferroportin mediates proton-coupled active transport of iron.

Shuang Li, Yihu Yang, Weikai Li,

As the sole iron exporter in humans, ferroportin controls systemic iron homeostasis through exporting iron into the blood plasma. The molecular mechanism of how ferroportin exports iron under various physiological settings remains unclear. Here we found that purified ferroportin incorporated into liposomes preferentially transports Fe2+ and exhibits lower affinities of ... Read more >>

Blood Adv (Blood advances)
[2020, 4(19):4758-4768]

Cited: 0 times

View full text PDF listing >>



An induced pluripotent stem cell model of Fanconi anemia reveals mechanisms of p53-driven progenitor cell differentiation.

William Marion, Steffen Boettcher, Sonya Ruiz-Torres, Edroaldo Lummertz da Rocha, Vanessa Lundin, Vivian Morris, Stephanie Chou, Anna M Zhao, Caroline Kubaczka, Olivia Aumais, Yosra Zhang, Akiko Shimamura, Thorsten M Schlaeger, Trista E North, Benjamin L Ebert, Susanne I Wells, George Q Daley, R Grant Rowe,

Fanconi anemia (FA) is a disorder of DNA repair that manifests as bone marrow (BM) failure. The lack of accurate murine models of FA has refocused efforts toward differentiation of patient-derived induced pluripotent stem cells (IPSCs) to hematopoietic progenitor cells (HPCs). However, an intact FA DNA repair pathway is required ... Read more >>

Blood Adv (Blood advances)
[2020, 4(19):4679-4692]

Cited: 0 times

View full text PDF listing >>



CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy.

Sarah Leong, Sarah Inglott, Foteini Papaleonidopoulou, Karen Orfinada, Philip Ancliff, Jack Bartram, Ben Carpenter, Adele K Fielding, Sara Ghorashian, Victoria Grandage, Rajeev Gupta, Rachael Hough, Asim Khwaja, Vesna Pavasovic, Anupama Rao, Sujith Samarasinghe, Ajay Vora, Marc R Mansour, David O'Connor,

Blood Adv (Blood advances)
[2020, 4(19):4665-4668]

Cited: 0 times

View full text PDF listing >>



Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19.

Mohammed Osman, Rehan M Faridi, Wendy Sligl, Meer-Taher Shabani-Rad, Poonam Dharmani-Khan, Arabesque Parker, Amit Kalra, Minal Borkar Tripathi, Jan Storek, Jan Willem Cohen Tervaert, Faisal M Khan,

The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-driven coronavirus disease 2019 (COVID-19) has caused unprecedented human death and has seriously threatened the global economy. Early data suggest a surge in proinflammatory cytokines in patients with severe COVID-19, which has been associated with poor outcomes. We recently postulated ... Read more >>

Blood Adv (Blood advances)
[2020, 4(20):5035-5039]

Cited: 0 times

View full text PDF listing >>



TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML.

Jayakumar Vadakekolathu, Catherine Lai, Stephen Reeder, Sarah E Church, Tressa Hood, Anbarasu Lourdusamy, Michael P Rettig, Ibrahim Aldoss, Anjali S Advani, John Godwin, Matthew J Wieduwilt, Martha Arellano, John Muth, Tung On Yau, Farhad Ravandi, Kendra Sweet, Heidi Altmann, Gemma A Foulds, Friedrich Stölzel, Jan Moritz Middeke, Marilena Ciciarello, Antonio Curti, Peter J M Valk, Bob Löwenberg, Ivana Gojo, Martin Bornhäuser, John F DiPersio, Jan K Davidson-Moncada, Sergio Rutella,

Somatic TP53 mutations and 17p deletions with genomic loss of TP53 occur in 37% to 46% of acute myeloid leukemia (AML) with adverse-risk cytogenetics and correlate with primary induction failure, high risk of relapse, and dismal prognosis. Herein, we aimed to characterize the immune landscape of TP53-mutated AML and determine ... Read more >>

Blood Adv (Blood advances)
[2020, 4(20):5011-5024]

Cited: 0 times

View full text PDF listing >>



Risk-assessment models for VTE and bleeding in hospitalized medical patients: an overview of systematic reviews.

Andrea J Darzi, Allen B Repp, Frederick A Spencer, Rami Z Morsi, Rana Charide, Itziar Etxeandia-Ikobaltzeta, Kenneth A Bauer, Allison E Burnett, Mary Cushman, Francesco Dentali, Susan R Kahn, Suely M Rezende, Neil A Zakai, Arnav Agarwal, Samer G Karam, Tamara Lotfi, Wojtek Wiercioch, Reem Waziry, Alfonso Iorio, Elie A Akl, Holger J Schünemann,

Multiple risk-assessment models (RAMs) for venous thromboembolism (VTE) in hospitalized medical patients have been developed. To inform the 2018 American Society of Hematology (ASH) guidelines on VTE, we conducted an overview of systematic reviews to identify and summarize evidence related to RAMs for VTE and bleeding in medical inpatients. We ... Read more >>

Blood Adv (Blood advances)
[2020, 4(19):4929-4944]

Cited: 0 times

View full text PDF listing >>



Diagnosis and treatment of mixed phenotype (T-myeloid/lymphoid) acute leukemia with novel ETV6-FGFR2 rearrangement.

Timothy Carll, Anand Patel, Benjamin Derman, Elizabeth Hyjek, Angela Lager, Pankhuri Wanjari, Jeremy Segal, Olatoyosi Odenike, Shiraz Fidai, Daniel Arber,

Blood Adv (Blood advances)
[2020, 4(19):4924-4928]

Cited: 0 times

View full text PDF listing >>



Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations.

Simone Feurstein, Ayodeji Adegunsoye, Danijela Mojsilovic, Rekha Vij, Allison H West DePersia, Padma Sheila Rajagopal, Afaf Osman, Robert H Collins, Raymond H Kim, Steven D Gore, Peter Greenberg, Lucy A Godley, Zejuan Li, Daniela Del Gaudio, Hari Prasanna Subramanian, Soma Das, Tom Walsh, Suleyman Gulsuner, Jeremy P Segal, Aliya N Husain, Sandeep Gurbuxani, Mary-Claire King, Mary E Strek, Jane E Churpek,

Telomere biology disorders (TBDs) present heterogeneously, ranging from infantile bone marrow failure associated with very short telomeres to adult-onset interstitial lung disease (ILD) with normal telomere length. Yield of genetic testing and phenotypic spectra for TBDs caused by the expanding list of telomere genes in adults remain understudied. Thus, we ... Read more >>

Blood Adv (Blood advances)
[2020, 4(19):4873-4886]

Cited: 0 times

View full text PDF listing >>



Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists.

Kristin L Koenig, Ying Huang, Emily K Dotson, Shane Sheredy, Seema A Bhat, John C Byrd, Emily Desmond, Jill Ford, Shauna Iarocci, Jeffrey A Jones, Margaret S Lucas, Mollie E Moran, Tracy E Wiczer, Jennifer A Woyach, Farrukh T Awan, Kerry A Rogers,

Venetoclax has efficacy in patients relapsing after B-cell receptor pathway inhibitors (BCRis); however, because of the risk of tumor lysis syndrome (TLS), a 5-week dose ramp-up is required to attain the target dose. Patients relapsing after BCRis frequently have proliferative disease, requiring a faster time to target dose than this ... Read more >>

Blood Adv (Blood advances)
[2020, 4(19):4860-4863]

Cited: 0 times

View full text PDF listing >>



Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients.

Kamel Laribi, Alix Baugier de Materre, Mohamad Sobh, Lorenzo Cerroni, Caterina Giovanna Valentini, Tomohiro Aoki, Ritsuro Suzuki, Kengo Takeuchi, Arthur E Frankel, Carlo Cota, David Ghez, Ronan Le Calloch, Livio Pagano, Tony Petrella,

The purpose of this study is to describe the clinical and prognostic features and to evaluate the outcome of different therapeutic approaches among patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who have been diagnosed and treated in different institutions. A total of 398 patients from 75 centers were included ... Read more >>

Blood Adv (Blood advances)
[2020, 4(19):4838-4848]

Cited: 0 times

View full text PDF listing >>



The Transplant Evaluation Rating Scale predicts overall survival after allogeneic hematopoietic stem cell transplantation.

Melhem M Solh, Dawn Speckhart, Scott R Solomon, Asad Bashey, Lawrence E Morris, Xu Zhang, H Kent Holland,

To evaluate the impact of psychosocial risks on post-hematopoietic stem cell transplantation (HSCT) outcomes, we prospectively conducted psychosocial assessment of 556 consecutive allogeneic HSCT patients who received their first allogeneic transplant at our center between 2003 and 2017. The Transplant Evaluation Rating Scale (TERS) score was prospectively assessed by a ... Read more >>

Blood Adv (Blood advances)
[2020, 4(19):4812-4821]

Cited: 0 times

View full text PDF listing >>



Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS.

Vikas Gupta, Soyoung Kim, Zhen-Huan Hu, Ying Liu, Mahmoud Aljurf, Ulrike Bacher, Amer Beitinjaneh, Jean-Yves Cahn, Jan Cerny, Edward Copelan, Shahinaz M Gadalla, Robert Peter Gale, Siddhartha Ganguly, Biju George, Aaron T Gerds, Usama Gergis, Betty K Hamilton, Shahrukh Hashmi, Gerhard C Hildebrandt, Rammurti T Kamble, Tamila Kindwall-Keller, Hillard M Lazarus, Jane L Liesveld, Mark Litzow, Richard T Maziarz, Taiga Nishihori, Richard F Olsson, David Rizzieri, Bipin N Savani, Sachiko Seo, Melhem Solh, Jeff Szer, Leo F Verdonck, Baldeep Wirk, Ann Woolfrey, Jean A Yared, Edwin P Alyea, Uday R Popat, Ronald M Sobecks, Bart L Scott, Ryotaro Nakamura, Wael Saber,

Comparative outcomes of allogeneic hematopoietic cell transplantation (HCT) for BCR-ABL1- myeloproliferative neoplasms (MPNs) in blast phase (MPN-BP) vs de novo acute myeloid leukemia (AML), and AML with prior myelodysplastic syndromes (MDSs; post-MDS AML), are unknown. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we compared HCT ... Read more >>

Blood Adv (Blood advances)
[2020, 4(19):4748-4757]

Cited: 0 times

View full text PDF listing >>



Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE).

Katharina Thom, Anthonie W A Lensing, Ildar Nurmeev, Fanny Bajolle, Damien Bonnet, Gili Kenet, M Patricia Massicotte, Zeynep Karakas, Joseph S Palumbo, Paola Saracco, Pascal Amedro, Juan Chain, Anthony K Chan, Takanari Ikeyama, Joyce C M Lam, Cynthia Gauger, Ákos Ferenc Pap, Madhurima Majumder, Dagmar Kubitza, William T Smith, Scott D Berkowitz, Martin H Prins, Paul Monagle, Guy Young, Christoph Male,

Anticoagulant treatment of pediatric central venous catheter-related venous thromboembolism (CVC-VTE) has not been specifically evaluated. In EINSTEIN-Jr, 500 children with any VTE received rivaroxaban or standard anticoagulants. A predefined analysis of the CVC-VTE cohort was performed. Children with CVC-VTE (age, birth to 17 years) were administered rivaroxaban or standard anticoagulants ... Read more >>

Blood Adv (Blood advances)
[2020, 4(19):4632-4639]

Cited: 0 times

View full text PDF listing >>



Abdel-Wahab N, Tayar JH, Fa'ak F, et al. Systematic review of observational studies reporting antiphospholipid antibodies in patients with solid tumors. Blood Adv. 2020;4(8):1746-1755.

Blood Adv (Blood advances)
[2020, 4(19):4605]

Cited: 0 times

View full text PDF listing >>



Morphologic remission status is limited compared to ΔN flow cytometry: a Children's Oncology Group AAML0531 report.

Lisa Eidenschink Brodersen, Robert B Gerbing, M Laura Pardo, Todd A Alonzo, Dana Paine, Wayne Fritschle, Fan-Chi Hsu, Jessica A Pollard, Richard Aplenc, Samir B Kahwash, Betsy Hirsch, Susana Ramondi, Denise Wells, E Anders Kolb, Alan S Gamis, Soheil Meshinchi, Michael R Loken,

Risk stratification for acute myeloid leukemia (AML) uses molecular and cytogenetic abnormalities identified at diagnosis. Response to therapy informs risk, and morphology continues to be used more frequently than flow cytometry. Herein, the largest cohort of pediatric patients prospectively assessed for measurable residual disease (MRD) by flow cytometry (N = ... Read more >>

Blood Adv (Blood advances)
[2020, 4(20):5050-5061]

Cited: 0 times

View full text PDF listing >>



Bleeding severity in patients with rare bleeding disorders: real-life data from the RBiN study.

Joline L Saes, Marieke J A Verhagen, Karina Meijer, Marjon H Cnossen, Roger E G Schutgens, Marjolein Peters, Laurens Nieuwenhuizen, Felix J M van der Meer, Ilmar C Kruis, Waander L van Heerde, Saskia E M Schols,

Patients with hereditary rare bleeding disorders (RBDs) present with diverse hemorrhagic symptoms. Correlation between factor activity levels and clinical bleeding severity is poor for most RBDs. Threshold factor activity levels have been previously described in relation to bleeding severity but have not yet been validated. The Rare Bleeding Disorders in ... Read more >>

Blood Adv (Blood advances)
[2020, 4(20):5025-5034]

Cited: 0 times

View full text PDF listing >>



Next-generation sequencing of 35 RHD variants in 16 253 serologically D- pregnant women in the Finnish population.

Silja M Tammi, Wajnat A Tounsi, Susanna Sainio, Michele Kiernan, Neil D Avent, Tracey E Madgett, Katri Haimila,

Fetal RHD screening for targeted routine antenatal anti-D prophylaxis has been implemented in many countries, including Finland, since the 2010s. Comprehensive knowledge of the RHD polymorphism in the population is essential for the performance and safety of the anti-D prophylaxis program. During the first 3 years of the national screening ... Read more >>

Blood Adv (Blood advances)
[2020, 4(20):4994-5001]

Cited: 0 times

View full text PDF listing >>



Augmenting emergency granulopoiesis with CpG conditioned mesenchymal stromal cells in murine neutropenic sepsis.

Julie Ng, Fei Guo, Anna E Marneth, Sailaja Ghanta, Min-Young Kwon, Joshua Keegan, Xiaoli Liu, Kyle T Wright, Baransel Kamaz, Laura A Cahill, Ann Mullally, Mark A Perrella, James A Lederer,

Patients with immune deficiencies from cancers and associated treatments represent a growing population within the intensive care unit with increased risk of morbidity and mortality from sepsis. Mesenchymal stromal cells (MSCs) are an integral part of the hematopoietic niche and express toll-like receptors, making them candidate cells to sense and ... Read more >>

Blood Adv (Blood advances)
[2020, 4(19):4965-4979]

Cited: 0 times

View full text PDF listing >>



MLL-TFE3: a novel and aggressive KMT2A fusion identified in infant leukemia.

Hansen J Kosasih, Nadia M Davidson, Stefan Bjelosevic, Emma Morrish, Margs S Brennan, Alicia Oshlack, Ricky W Johnstone, Gabriela Brumatti, Seong L Khaw, Paul G Ekert,

Blood Adv (Blood advances)
[2020, 4(19):4918-4923]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
1.2815 s